Osmetech: Star Trek technology today. The real McCoy

Well my view is that OPTI has proved a success and if we work on the split of sales in the one month reported in last years final accounts -

all in US $

1.055m incs new sales of 47% and 53% of sales related to propriety reagents. Therefore

0.495m for new sales and 0.560m for reagents.

On top of this is the purchase from China (US$760and the ongoing reagents...the income from this source for the last 6 months could easily top US$6 to 7 m - which dwarfes the cash in bank held from the recent fundraising exercises.